TG Therapeutics (TGTX) Scheduled to Post Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is scheduled to be posting its quarterly earnings results before the market opens on Monday, November 4th. Analysts expect TG Therapeutics to post earnings of $0.04 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The firm had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business’s revenue was up 357.0% compared to the same quarter last year. During the same period last year, the company earned ($0.34) earnings per share. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Stock Up 7.3 %

TGTX stock opened at $26.90 on Friday. TG Therapeutics has a twelve month low of $9.81 and a twelve month high of $26.99. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 44.10 and a beta of 2.21. The business has a 50 day moving average price of $23.51 and a two-hundred day moving average price of $20.01. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

Analysts Set New Price Targets

TGTX has been the subject of a number of recent analyst reports. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. The Goldman Sachs Group raised their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. B. Riley raised their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.33.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.